| Year |
Citation |
Score |
| 2024 |
Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, et al. Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. Proceedings of the National Academy of Sciences of the United States of America. 121: e2322068121. PMID 39042692 DOI: 10.1073/pnas.2322068121 |
0.324 |
|
| 2024 |
Zuley ML, Silverstein J, Logue D, Morgan RS, Bhargava R, McAuliffe PF, Brufsky AM, Bandos AI, Nishikawa RM. Organizational Breast Cancer Data Mart: A Solution for Assessing Outcomes of Imaging and Treatment. Jco Clinical Cancer Informatics. 8: e2300193. PMID 38621193 DOI: 10.1200/CCI.23.00193 |
0.305 |
|
| 2023 |
Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, et al. Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nature Cancer. PMID 37012402 DOI: 10.1038/s43018-023-00549-4 |
0.301 |
|
| 2023 |
Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, et al. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nature Cancer. PMID 36927792 DOI: 10.1038/s43018-023-00527-w |
0.353 |
|
| 2022 |
Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, Simpson LA, Vennam S, Khan A, Cisneros L, Hardman T, Harmon B, Couch F, Gallagher K, Kilgore M, ... ... McAuliffe PF, et al. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. PMID 36400020 DOI: 10.1016/j.ccell.2022.10.021 |
0.358 |
|
| 2022 |
Carleton N, Nasrazadani A, Gade K, Beriwal S, Barry PN, Brufsky AM, Bhargava R, Berg WA, Zuley ML, van Londen GJ, Marroquin OC, Thull DL, Mai PL, Diego EJ, Lotze MT, ... ... McAuliffe PF, et al. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. The Lancet. Healthy Longevity. 3: e54-e66. PMID 35047868 DOI: 10.1016/s2666-7568(21)00280-4 |
0.328 |
|
| 2021 |
Myers SP, Ahrendt GM, Lee JS, Steiman J, Soran A, Johnson RR, McAuliffe PF, Diego EJ. ASO Visual Abstract: Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgical Oncology. PMID 34716513 DOI: 10.1245/s10434-021-10255-z |
0.339 |
|
| 2021 |
Myers SP, Ahrendt GM, Lee JS, Steiman JG, Soran A, Johnson RR, McAuliffe PF, Diego EJ. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgical Oncology. PMID 34142288 DOI: 10.1245/s10434-021-10195-8 |
0.348 |
|
| 2021 |
Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, ... ... McAuliffe PF, et al. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. Jama Network Open. 4: e216322. PMID 33856473 DOI: 10.1001/jamanetworkopen.2021.6322 |
0.311 |
|
| 2020 |
Atkinson JM, Sreekumar S, Levine KM, Sikora MJ, Chen J, Dabbs DJ, Meier C, Basudan A, Tasdemir N, Boone D, McAuliffe PF, Jankowitz RC, Lee AV, Oesterreich S. Abstract P1-21-03: Unique estrogen receptor alpha turnover, regulation and targeting in invasive lobular breast carcinoma Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-21-03 |
0.319 |
|
| 2019 |
Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, Brufsky AM, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, et al. Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30723293 DOI: 10.1038/s41379-019-0208-x |
0.353 |
|
| 2018 |
Clark BZ, Farrugia DJ, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. American Journal of Clinical Pathology. PMID 29481634 DOI: 10.1093/ajcp/aqx168 |
0.302 |
|
| 2018 |
Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA. Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute. PMID 29471462 DOI: 10.1093/jnci/djy014 |
0.32 |
|
| 2017 |
Koleck TA, Bender CM, Clark BZ, Ryan CM, Ghotkar P, Brufsky A, McAuliffe PF, Rastogi P, Sereika SM, Conley YP. An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. Breast Cancer (Dove Medical Press). 9: 95-110. PMID 28424560 DOI: 10.2147/BCTT.S123785 |
0.325 |
|
| 2017 |
Farrugia D, Landmann A, McAuliffe P, Diego E, Johnson R, Bonaventura M, Soran A, Dabbs D, Clark B, Lembersky B, Puhalla S, Brufsky A, Jankowitz R, Davidson N, Ahrendt G, et al. Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-09-14 |
0.328 |
|
| 2016 |
Soran A, Bhargava R, Johnson R, Ahrendt G, Bonaventura M, Diego E, McAuliffe PF, Serrano M, Menekse E, Sezgin E, McGuire KP. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Disease. 36: 65-71. PMID 27662272 DOI: 10.3233/Bd-150199 |
0.32 |
|
| 2016 |
Farrugia DJ, Landmann A, Diego E, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Jankowitz RC, Lembersky BC, Davidson NE, Ahrendt GM, et al. Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy. Journal of Clinical Oncology. 34: e23265-e23265. DOI: 10.1200/JCO.2016.34.15_suppl.e23265 |
0.313 |
|
| 2016 |
Landmann A, Farrugia DJ, Diego E, Bonaventura M, Soran A, Johnson R, Dabbs DJ, Clark B, Brufsky A, Davidson NE, Lembersky BC, Jankowitz RC, Puhalla S, Ahrendt GM, McAuliffe PF, et al. HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors? Journal of Clinical Oncology. 34: 612-612. DOI: 10.1200/JCO.2016.34.15_SUPPL.612 |
0.323 |
|
| 2016 |
Jankowitz R, McAuliffe P, Sikora M, Butler L, Ahrendt G, Johnson R, Diego E, Bonaventura M, Puhalla S, Lembersky B, Clark B, Brufsky A, Kurland B, Davidson N, Dabbs D, et al. Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-14 |
0.333 |
|
| 2015 |
McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, et al. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. Plos One. 10: e0136851. PMID 26325287 DOI: 10.1371/Journal.Pone.0136851 |
0.36 |
|
| 2015 |
Soran A, Menekse E, McKolanis J, McAuliffe PF, McGuire KP, Diego E, Bonaventura M, Johnson R, Ahrendt GM, Finn OJ. Is nipple aspirate fluid (NAF) a reliable source to identify biomarkers in breast cancer? A feasibility study. Journal of Clinical Oncology. 33: e22101-e22101. DOI: 10.1200/Jco.2015.33.15_Suppl.E22101 |
0.309 |
|
| 2015 |
McAuliffe P. Ductal Carcinoma In Situ Breast Disease: Diagnosis and Pathology. 1: 131-143. DOI: 10.1007/978-3-319-22843-3_7 |
0.365 |
|
| 2014 |
McAuliffe PF, Akcakanat A, Evans K, Eterovic AK, Zhao H, Chen K, Sangai T, Chen H, Do K, Holder AM, Sharma C, Symmans WF, Gagea M, Naff KA, Sahin A, et al. Abstract 1186: Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment Cancer Research. 74: 1186-1186. DOI: 10.1158/1538-7445.Am2014-1186 |
0.344 |
|
| 2013 |
Mcauliffe PF. How to Maximize the Potential of mTOR Inhibitors in Breast Cancer-More Questions Than Answers. Oncology (Williston Park, N.Y.). 27. PMID 25188240 |
0.302 |
|
| 2013 |
McAuliffe PF, Danoff S, Shapiro SD, Davidson NE. Treatment for breast cancer: is time really of the essence? Journal of the National Cancer Institute. 105: 80-2. PMID 23264682 DOI: 10.1093/jnci/djs524 |
0.319 |
|
| 2011 |
McAuliffe PF, Gonzalez-Angulo A, Akcakanat A, Chen H, Hale KS, Do K, Sharma C, Symmans WF, Mills GB, Meric-Bernstam F. Characterization of patient-derived breast cancer xenografts demonstrates molecular evolution Journal of the American College of Surgeons. 213: S28. DOI: 10.1016/J.JAMCOLLSURG.2011.06.049 |
0.334 |
|
| 2005 |
Camp ER, McAuliffe PF, Gilroy JS, Morris CG, Lind DS, Mendenhall NP, Copeland EM. Minimizing local recurrence after breast conserving therapy using intraoperative shaved margins to determine pathologic tumor clearance. Journal of the American College of Surgeons. 201: 855-61. PMID 16310688 DOI: 10.1016/j.jamcollsurg.2005.06.274 |
0.326 |
|
| Show low-probability matches. |